Brought to you by 
PainCeptor Pharma is result of Antalium, Neuroceptor merger
01 Apr 2004
Executive Summary
Neurology therapeutics companies Antalium and Neuroceptor have merged to form PainCeptor Pharma, a new Canadian company that focuses on treatments for chronic and acute pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PainCeptor Pharma is result of Antalium, Neuroceptor merger
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice